EUVIMEDEUVIMED entdecken
Crossref

Use of Hydrochlorothiazide in the United States Following Label Update About Skin Cancer Risk

Cheng Chen iD, Efe Eworuke, Ashish Rai, Laura Hou, Jenice S Ko, Mary Ross Southworth, José J Hernández-Muñoz, Mingfeng Zhang iD

Pharmacoepidemiology and Drug Safety · 2024

DOI: 10.1002/pds.70040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Cheng Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. Hauptthemen laut MEDLINE: Hydrochlorothiazide, Skin Neoplasms, Drug Labeling, United States Food and Drug Administration. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: U.S. Food and Drug Administration, FDA HHS, Food and Drug Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

On August 20, 2020, the United States (U.S.) Food and Drug Administration (FDA) issued a Drug Safety Communication (DSC) along with labeling updates to inform the public about a small increased risk of non‐melanoma skin cancer (NMSC) associated with hydrochlorothiazide (HCTZ) use. This study aims to assess whether the DSC impacted HCTZ use in the U.S.

Methods

We conducted a trend analysis in the Sentinel Distributed Database using national healthcare administrative data from January 2017 to November 2022. We identified two cohorts each month: An overall cohort of all enrollees and a skin cancer cohort of those with a history of NMSC. For each cohort, we plotted the monthly proportion of patients receiving HCTZ‐containing products among those receiving any thiazide diuretics. We performed interrupted time series analyses to quantify the impact of the DSC on these monthly proportions. Secondary analyses were conducted on the proportion of HCTZ users among patients receiving any antihypertensives.

Results

In the overall cohort, the DSC was only associated with a statistically significant but clinically negligible trend change of monthly HCTZ proportion within this cohort (0.018%; 95% CI, 0.012%–0.025%). Similar results were observed in the skin cancer cohort. The secondary analysis found no significant level change or trend change in the monthly proportion of HCTZ use among antihypertensive users.

Conclusions

We did not observe significant changes in HCTZ use following the DSC about its NMSC risk, among the overall population and those with a history of NMSC. Our findings were in accordance with the DSC recommendation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydrochlorothiazideSkin NeoplasmsDrug LabelingUnited States Food and Drug AdministrationAntihypertensive AgentsHumansUnited StatesFemaleMaleMiddle AgedAgedAdultDatabases, FactualSodium Chloride Symporter InhibitorsInterrupted Time Series AnalysisCohort Studies

Stichwörter der Autor:innen

antihypertensivesdrug safety communicationdrug utilizationhydrochlorothiazideimpact of regulatory decisionlabel updatereal world datareal world evidence

Substanzen

HydrochlorothiazideAntihypertensive AgentsSodium Chloride Symporter Inhibitors

Autor:innen und Institutionen

  • Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
  • Epidemiology and Drug Safety, IQVIA Real World Solutions, Washington, DC, USA.
  • Department of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Cardiology and Nephrology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.

ORCID-Profile: Cheng Chen, Mingfeng Zhang

Förderung

  • U.S. Food and Drug Administration
  • FDA HHS
  • Food and Drug Administration

Zitieren

APA

Chen, C., Eworuke, E., Rai, A., Hou, L., Ko, J. S., Southworth, M. R., Hernández-Muñoz, J. J., & Zhang, M. (2024). Use of Hydrochlorothiazide in the United States Following Label Update About Skin Cancer Risk. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70040

Vancouver

Chen C, Eworuke E, Rai A, Hou L, Ko JS, Southworth MR, et al. Use of Hydrochlorothiazide in the United States Following Label Update About Skin Cancer Risk. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.70040

BibTeX
@article{Chen2024,
  author = {Chen, Cheng and Eworuke, Efe and Rai, Ashish and Hou, Laura and Ko, Jenice S and Southworth, Mary Ross and Hernández-Muñoz, José J and Zhang, Mingfeng},
  title = {Use of Hydrochlorothiazide in the United States Following Label Update About Skin Cancer Risk},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2024},
  doi = {10.1002/pds.70040}
}
Kostenlos starten →